Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates.

Read this article:
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

Related Posts